Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.

Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.

Zhitong Finance22:25 ET

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking Alpha17:01 ET

Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk

WSJDec 10 10:06 ET

Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'

BenzingaDec 10 08:27 ET

Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development

BusinesswireDec 10 07:00 ET

Express News | Novo Nordisk Says Investment Aimed At Expanding Enzymes Output Used For The Production Of Insulin, GLP-1 Medicines

BenzingaDec 9 13:30 ET